FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385751567> ?p ?o ?g. }

• W4385751567 abstract "Abstract Background Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors. Methods This retrospective study included patients with locally advanced or metastatic penile squamous cell carcinoma receiving immune checkpoint inhibitors between 2015 and 2022 across 24 centers in the United States, Europe, and Asia. Overall survival and progression-free survival were estimated using the Kaplan-Meier method. Objective response rates were determined per Response Evaluation Criteria in Solid Tumours 1.1 criteria. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events, version 5.0. Two-sided statistical tests were used for comparisons. Results Among 92 patients, 8 (8.7%) were Asian, 6 (6.5%) were Black, and 24 (29%) were Hispanic and/or Latinx. Median (interquartile range) age was 62 (53-70) years. In all, 83 (90%) had metastatic penile squamous cell carcinoma, and 74 (80%) had received at least second-line treatment. Most patients received pembrolizumab monotherapy (n = 26 [28%]), combination nivolumab-ipilimumab with or without multitargeted tyrosine kinase inhibitors (n = 23 [25%]), or nivolumab (n = 16 [17%]) or cemiplimab (n = 15 [16%]) monotherapies. Median overall and progression-free survival were 9.8 months (95% confidence interval = 7.7 to 12.8 months) and 3.2 months (95% confidence interval = 2.5 to 4.2 months), respectively. The objective response rate was 13% (n = 11/85) in the overall cohort and 35% (n = 7/20) in patients with lymph node–only metastases. Visceral metastases, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or higher, and a higher neutrophil/lymphocyte ratio were associated with worse overall survival. Treatment-related adverse events occurred in 27 (29%) patients, and 9.8% (n = 9) of the events were grade 3 or higher. Conclusions Immune checkpoint inhibitors are active in a subset of patients with penile squamous cell carcinoma. Future translational studies are warranted to identify patients more likely to derive clinical benefit from immune checkpoint inhibitors." @default.
• W4385751567 created "2023-08-12" @default.
• W4385751567 creator A5000817838 @default.
• W4385751567 creator A5000997350 @default.
• W4385751567 creator A5002745641 @default.
• W4385751567 creator A5003892243 @default.
• W4385751567 creator A5004554295 @default.
• W4385751567 creator A5006629788 @default.
• W4385751567 creator A5011367118 @default.
• W4385751567 creator A5012316179 @default.
• W4385751567 creator A5013832255 @default.
• W4385751567 creator A5013913173 @default.
• W4385751567 creator A5015959166 @default.
• W4385751567 creator A5018398109 @default.
• W4385751567 creator A5024065466 @default.
• W4385751567 creator A5024147987 @default.
• W4385751567 creator A5027856039 @default.
• W4385751567 creator A5028897583 @default.
• W4385751567 creator A5032055062 @default.
• W4385751567 creator A5032901007 @default.
• W4385751567 creator A5033353421 @default.
• W4385751567 creator A5033450748 @default.
• W4385751567 creator A5034433849 @default.
• W4385751567 creator A5035120623 @default.
• W4385751567 creator A5037495975 @default.
• W4385751567 creator A5037756908 @default.
• W4385751567 creator A5039083730 @default.
• W4385751567 creator A5042850076 @default.
• W4385751567 creator A5046974113 @default.
• W4385751567 creator A5047686363 @default.
• W4385751567 creator A5047689900 @default.
• W4385751567 creator A5049013923 @default.
• W4385751567 creator A5049657362 @default.
• W4385751567 creator A5052069729 @default.
• W4385751567 creator A5053079426 @default.
• W4385751567 creator A5053588971 @default.
• W4385751567 creator A5054484092 @default.
• W4385751567 creator A5054850662 @default.
• W4385751567 creator A5058325420 @default.
• W4385751567 creator A5060954139 @default.
• W4385751567 creator A5061950952 @default.
• W4385751567 creator A5062276540 @default.
• W4385751567 creator A5063838757 @default.
• W4385751567 creator A5065813292 @default.
• W4385751567 creator A5068197546 @default.
• W4385751567 creator A5068433389 @default.
• W4385751567 creator A5071318362 @default.
• W4385751567 creator A5073084267 @default.
• W4385751567 creator A5073541359 @default.
• W4385751567 creator A5075514238 @default.
• W4385751567 creator A5080526034 @default.
• W4385751567 creator A5082984172 @default.
• W4385751567 creator A5083331837 @default.
• W4385751567 creator A5083920381 @default.
• W4385751567 creator A5086546163 @default.
• W4385751567 creator A5089107759 @default.
• W4385751567 creator A5090727184 @default.
• W4385751567 date "2023-08-11" @default.
• W4385751567 modified "2023-10-15" @default.
• W4385751567 title "Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors" @default.
• W4385751567 cites W1603787877 @default.
• W4385751567 cites W1940241680 @default.
• W4385751567 cites W1989696254 @default.
• W4385751567 cites W1999372811 @default.
• W4385751567 cites W2011730845 @default.
• W4385751567 cites W2101270203 @default.
• W4385751567 cites W2111539500 @default.
• W4385751567 cites W2113430686 @default.
• W4385751567 cites W2118245082 @default.
• W4385751567 cites W2139280553 @default.
• W4385751567 cites W2401074278 @default.
• W4385751567 cites W2522813255 @default.
• W4385751567 cites W2529484692 @default.
• W4385751567 cites W2565952597 @default.
• W4385751567 cites W2763584377 @default.
• W4385751567 cites W2783295481 @default.
• W4385751567 cites W2797220830 @default.
• W4385751567 cites W2803451300 @default.
• W4385751567 cites W2805968856 @default.
• W4385751567 cites W2888676937 @default.
• W4385751567 cites W2893921328 @default.
• W4385751567 cites W2910312762 @default.
• W4385751567 cites W2972824578 @default.
• W4385751567 cites W2980908195 @default.
• W4385751567 cites W2984359187 @default.
• W4385751567 cites W2994692693 @default.
• W4385751567 cites W2994834257 @default.
• W4385751567 cites W3006767832 @default.
• W4385751567 cites W3021295141 @default.
• W4385751567 cites W3040316325 @default.
• W4385751567 cites W3083986479 @default.
• W4385751567 cites W3086850485 @default.
• W4385751567 cites W3098769160 @default.
• W4385751567 cites W3110528877 @default.
• W4385751567 cites W3114760040 @default.
• W4385751567 cites W3118466670 @default.
• W4385751567 cites W3118924526 @default.
• W4385751567 cites W3127371144 @default.
• W4385751567 cites W3139336530 @default.
• W4385751567 cites W3174461358 @default.

• next